Berger Dietmar 4

What Happened
Dietmar Berger, Chief Medical Officer of Gilead Sciences (GILD), had 533 restricted stock units convert into common shares on June 10, 2026. To cover tax withholding, 263 of those shares were surrendered at $121.48 per share for a withholding value of $31,949, leaving a net 270 shares issued to Berger. This was a vesting/conversion event (not an open‑market purchase or sale) and is generally a routine tax withholding.

Key Details

• Transaction date: 2026-06-10; Form filed 2026-06-11 (timely filing).
• Conversion/vesting: 533 RSUs converted to shares (transaction code M).
• Tax withholding: 263 shares withheld (transaction code F) at $121.48/share = $31,949.
• Net shares issued to insider: 270 (533 converted − 263 withheld).
• Shares owned after transaction: not reported in the provided excerpt.
• Footnotes: F1 — each RSU = right to one share; F2 — RSUs follow a 4‑year vesting schedule (25% at year 1, then 6.25% quarterly).
• Transaction types: M = exercise/conversion of derivative (RSU vesting), F = tax withholding.

Context
This action reflects RSU vesting and routine tax withholding rather than an investment decision; withheld shares are commonly used to satisfy tax liabilities. For insiders, conversions/vestings are typical compensation events and do not alone indicate buy/sell sentiment.